REPLACEMENT OF FINGER AND GROWTH-FACTOR DOMAINS OF TISSUE PLASMINOGEN-ACTIVATOR WITH PLASMINOGEN KRINGLE-1 - BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF A NOVEL CHIMERA CONTAINING A HIGH-AFFINITY FIBRIN-BINDING DOMAIN LINKED TO A HETEROLOGOUS PROTEIN

A novel triple-kringle plasminogen activator protein, PK1-DELTA-FE1X, has been produced which is a genetic chimera between the fibrin binding kringle 1 domain of plasminogen and the two kringles and serine protease domains of naturally occurring wild-type tissue plasminogen activator (wt t-PA). This chimera also contains a modification to prevent high mannose type N-linked glycosylation on kringle 1 of t-PA. PK1-DELTA-FE1X is biochemically and fibrinolytically similar to wt t-PA in vitro but retains the decreased plasma clearance rate characteristic of other t-PA variants which lack fibronectin finger-like and epidermal growth factor domains. The serine protease domain of PK1-DELTA-FE1X exhibits the amidolytic activity characteristic of wt t-PA. In an indirect coupled plasminogen activator assay, the specific activity of PK1-DELTA-FE1X is approximately 1.4 times greater than that of wt t-PA. In a fibrin film-binding assay, greater binding to untreated fibrin is observed with wt t-PA than with PK1-DELTA-FE1X. However, following limited plasmin digestion of the fibrin film, PK1-DELTA-FE1X binding increases to the level observed with wt t-PA. The incremental binding to plasmin-digested fibrin observed with PK1-DELTA-FE1X is eliminated if plasmin digestion of the fibrin film is followed by carboxypeptidase B treatment. This result suggests that plasminogen kringle 1 binds plasmin-digested fibrin even after recombination with a heterologous protein. The fibrinolytic activity of PK1-DELTA-FE1X in human plasma clot lysis assays was similar to that of wt t-PA at activator concentrations of approximately 1-mu-g/ml. At substantially lower concentrations, approximately 0.1-mu-g/ml, PK1-DELTA-FE1X was only slightly less active than wt t-PA. Pharmacokinetic analysis showed that wt t-PA activity is cleared approximately 15 times as rapidly as PK1-DELTA-FE1X following intravenous bolus injection. In a rabbit jugular vein clot lysis model, intravenous bolus injection of 0.06 mg/kg of PK1-DELTA-FE1X showed greater thrombolytic potency than a similar administration of 0.5 mg/kg of wt t-PA. Thus it appears that in vitro exon shuffling techniques can be used to generate novel fibrinolytic agents which biochemically and pharmacologically represent the combination of individual domains of naturally occurring proteins.